PD168393 is a first generation quinazolin amine irreversible EGFR inhibitors that alkylates Cys-773 within the ATP binding pocket [1]. While this compound did not progress into clinical application due to limited effect on EGFR mutant T790M, numerous EGFR research used this as a reference compound to explore new combinatory treatment strategies, evaluate application of EGFR inhibitors in new in vitro and in vivo cancer model systems, and compare mechanisms of action for new generations of EGFR inhibitors [2,3].

PD168393 is a first generation quinazolin amine irreversible EGFR inhibitors that alkylates Cys-773 within the ATP binding pocket [1]. While this compound did not progress into clinical application due to limited effect on EGFR mutant T790M, numerous EGFR research used this as a reference compound to explore new combinatory treatment strategies, evaluate application of EGFR inhibitors in new in vitro and in vivo cancer model systems, and compare mechanisms of action for new generations of EGFR inhibitors [2,3].